Novavax (NVAX) Net Equity Issued and Repurchased (2010 - 2024)
Novavax (NVAX) posted quarterly Net Equity Issued and Repurchased of $256.4 million for Q2 2024, up 313.66% year-over-year from $62.0 million in Q3 2023, and up 3636.67% quarter-over-quarter from $6.9 million in Q1 2024.
Novavax (NVAX) Net Equity Issued and Repurchased (2010 - 2024) Analysis & Trends
Novavax's Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $256.4 million for Q2 2024.
- In Q2 2024, Net Equity Issued and Repurchased rose 313.66% year-over-year to $256.4 million; the TTM figure through Mar 2025 stood at $256.4 million (up 48.99% YoY), while the FY2024 annual figure was $263.3 million, down 26.92% from the prior year.
- Net Equity Issued and Repurchased for Q2 2024 stood at $256.4 million, up from $6.9 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $564.9 million in Q1 2021, with the low at $1.5 million in Q2 2020.
- The 5-year median for Net Equity Issued and Repurchased is $179.4 million (2022), against an average of $192.6 million.
- The sharpest annual moves came in 2020 and 2022: Net Equity Issued and Repurchased jumped 49900.0% in 2020, then slumped 68.24% in 2022.
- Novavax's Net Equity Issued and Repurchased stood at $428.6 million in 2020, then surged by 31.81% to $564.9 million in 2021, then slumped by 87.63% to $69.8 million in 2022, then soared by 47.82% to $103.2 million in 2023, then soared by 148.34% to $256.4 million in 2024.
- Business Quant data shows NVAX's Net Equity Issued and Repurchased at $256.4 million in Q2 2024, $6.9 million in Q1 2024, and $103.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 256.41 Mn |
| Jun 30, 2024 | 256.41 Mn |
| Mar 31, 2024 | 6.86 Mn |
| Mar 31, 2024 | 6.86 Mn |
| Dec 31, 2023 | 103.25 Mn |
| Dec 31, 2023 | 103.25 Mn |
| Jun 30, 2023 | 61.99 Mn |
| Jun 30, 2023 | 61.99 Mn |
| Dec 31, 2022 | 69.85 Mn |
| Dec 31, 2022 | 69.85 Mn |
| Mar 31, 2022 | 179.39 Mn |
| Mar 31, 2022 | 179.39 Mn |
| Mar 31, 2021 | 564.86 Mn |
| Mar 31, 2021 | 564.86 Mn |
| Dec 31, 2020 | 428.55 Mn |
| Dec 31, 2020 | 428.55 Mn |
| Sep 30, 2020 | 259.65 Mn |
| Sep 30, 2020 | 259.65 Mn |
| Jun 30, 2020 | 1.50 Mn |
| Jun 30, 2020 | 1.50 Mn |